SOAT1 and essential thrombocythemia: Currently, the only approved targeted therapy for patients with myelofibrotic-phase ET and for non-transplanted patients with PMF is the JAK1/JAK2 inhibitor ruxolitinib, which aims to decrease the activation of the JAK2/STAT pathway [19].